MEI Pharma, Inc.
MEIP
$2.04
$0.042.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 65.30M | 66.75M | 72.65M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 0.00 | 65.30M | 66.75M | 72.65M |
| Cost of Revenue | 10.73M | 14.35M | 15.94M | 14.24M | 22.94M |
| Gross Profit | -10.73M | -14.35M | 49.36M | 52.52M | 49.71M |
| SG&A Expenses | 14.23M | 19.81M | 22.95M | 28.73M | 31.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.19M | 34.57M | 39.31M | 42.78M | 54.04M |
| Operating Income | -25.19M | -34.57M | 25.99M | 23.97M | 18.61M |
| Income Before Tax | -38.22M | -46.60M | 17.78M | 26.16M | 19.84M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -38.22 | -46.60 | 17.78 | 26.16 | 19.84 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.22M | -46.60M | 17.78M | 26.16M | 19.84M |
| EBIT | -25.19M | -34.57M | 25.99M | 23.97M | 18.61M |
| EBITDA | -24.62M | -33.91M | 26.37M | 24.33M | 18.98M |
| EPS Basic | -5.74 | -6.99 | 2.67 | 3.93 | 2.98 |
| Normalized Basic EPS | -2.14 | -3.01 | 2.74 | 2.60 | 2.12 |
| EPS Diluted | -5.74 | -6.99 | 2.67 | 3.93 | 2.98 |
| Normalized Diluted EPS | -2.14 | -3.01 | 2.74 | 2.60 | 2.12 |
| Average Basic Shares Outstanding | 26.65M | 26.65M | 26.65M | 26.65M | 26.65M |
| Average Diluted Shares Outstanding | 26.65M | 26.65M | 26.65M | 26.65M | 26.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |